dc.contributor.author | BİLGİNER, YELDA | |
dc.contributor.author | Ayaz, Nuray | |
dc.contributor.author | Calguneri, Meral | |
dc.contributor.author | ÖZEN, SEZA | |
dc.date.accessioned | 2021-03-03T19:16:34Z | |
dc.date.available | 2021-03-03T19:16:34Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | ÖZEN S., BİLGİNER Y., Ayaz N., Calguneri M., "Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine", JOURNAL OF RHEUMATOLOGY, cilt.38, sa.3, ss.516-518, 2011 | |
dc.identifier.issn | 0315-162X | |
dc.identifier.other | av_53a60992-b208-4602-a3ae-0bfdefb9dde0 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/59286 | |
dc.identifier.uri | https://doi.org/10.3899/jrheum.100718 | |
dc.description.abstract | Objective. Familial Mediterranean fever (FMF) is a recessively inherited autoinflammatory disorder characterized by recurrent attacks of fever and serositis. Although colchicine is the standard therapy for preventing attacks and suppressing inflammation, 5%-10% of compliant patients are colchicine-resistant. We report the effect of anti-tumor necrosis factor therapy (etanercept) and anti-interleukin 1 (IL-1) treatment (anakinra) in 6 cases resistant to colchicine therapy. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | İmmünoloji ve Romatoloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ROMATOLOJİ | |
dc.title | Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF RHEUMATOLOGY | |
dc.contributor.department | Hacettepe Üniversitesi , Tıp Fakültesi (Türkçe) , Dahili Tıp Bilimleri Bölümü | |
dc.identifier.volume | 38 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 516 | |
dc.identifier.endpage | 518 | |
dc.contributor.firstauthorID | 838506 | |